Toronto, ON; June 16, 2016 – A New Look at Oral Dysplasia, recently published in Oral Health, recognizes the need for a more effective biomarker for oral premalignant lesions. The article highlights Straticyte’s more objective assessment capability that may revolutionize patient care.
Written by Dr. Barrie M. Renick, B.Sc.,D.D.S., M.R.D.C., Oral and Maxillofacial Surgeon, the article discusses the limitations of current practice that has led to a widely recognized urgent need for more effective prognostic biomarkers. Healthcare providers clearly want a risk assessment for cancer development in patients diagnosed with oral premalignant lesions. This risk assessment would provide some clarity for patients and guidance for healthcare providers.
The article A New Look at Oral Dysplasia can be viewed here.